Acasti Pharma Common Stock Net 2014-2024 | GRCE

Acasti Pharma common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.
Acasti Pharma Annual Common Stock Net
(Millions of US $)
2024 $261
2023 $258
2022 $258
2021 $197
2020 $137
2019 $111
2018 $57
2017 $51
2016 $48
2015 $55
2015 $
2014 $58
2014 $
2013 $29
2013 $
Acasti Pharma Quarterly Common Stock Net
(Millions of US $)
2024-06-30 $261
2024-03-31 $261
2023-12-31 $261
2023-09-30 $261
2023-06-30 $258
2023-03-31 $258
2022-12-31 $258
2022-09-30 $258
2022-06-30 $258
2022-03-31 $258
2021-12-31 $258
2021-09-30 $258
2021-06-30 $197
2021-03-31 $197
2020-12-31 $162
2020-09-30 $143
2020-06-30 $139
2020-03-31 $137
2019-12-31 $124
2019-09-30 $115
2019-06-30 $97
2019-03-31 $111
2018-12-31 $98
2018-09-30 $61
2018-06-30 $62
2018-03-31 $57
2017-12-31 $56
2017-09-30 $53
2017-06-30 $50
2017-02-28 $51
2016-11-30 $47
2016-08-31 $48
2016-05-31 $48
2016-03-31 $48
2016-02-29
2015-12-31 $47
2015-09-30 $48
2015-06-30 $50
2015-03-31 $55
2014-12-31 $55
2014-09-30 $57
2014-06-30 $56
2014-03-31 $58
2014-02-28
2013-12-31 $45
2013-09-30 $43
2013-06-30 $28
2013-03-31 $29
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00